Harmony Biosciences Holdings (HRMY) Stock Overview
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HRMY from our risk checks.
HRMY Community Fair Values
Create NarrativeSee what 175 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Harmony Biosciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.14 |
| 52 Week High | US$40.87 |
| 52 Week Low | US$25.52 |
| Beta | 0.91 |
| 1 Month Change | 12.94% |
| 3 Month Change | 25.30% |
| 1 Year Change | 4.75% |
| 3 Year Change | 17.97% |
| 5 Year Change | 16.21% |
| Change since IPO | 3.05% |
Recent News & Updates
Seeking Alpha • Aug 05
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
Summary Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold. Read the full article on Seeking Alpha
Narrative Update • Aug 04
HRMY: IP Litigation Outcome Will Support Future Rare Neurology Pipeline Upside
Analysts have raised their price target on Harmony Biosciences Holdings to $36 from $30, citing updated views on the company's intellectual property litigation related to Wakix and a revised set of valuation inputs. What's in the News for Harmony Biosciences Holdings Harmony Biosciences Holdings reiterated full year 2026 earnings guidance, with expected net product revenue in a range of US$1.0b to US$1.04b.Recent updates
Seeking Alpha • Aug 05
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated
Summary Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold. Read the full article on Seeking AlphaNarrative Update • Aug 04
HRMY: IP Litigation Outcome Will Support Future Rare Neurology Pipeline Upside
Analysts have raised their price target on Harmony Biosciences Holdings to $36 from $30, citing updated views on the company's intellectual property litigation related to Wakix and a revised set of valuation inputs. What's in the News for Harmony Biosciences Holdings Harmony Biosciences Holdings reiterated full year 2026 earnings guidance, with expected net product revenue in a range of US$1.0b to US$1.04b.Narrative Update • Jun 19
HRMY: Patent Litigation Resolution Will Support Rare Neurology Pipeline Upside
Harmony Biosciences Holdings' analyst price target has been raised by $10, as analysts point to a major positive development in patent litigation and view recent share weakness as excessive, given updated expectations around growth, profitability, and future P/E assumptions. Analyst Commentary on Harmony Biosciences Holdings Stock Recent Street research on Harmony Biosciences Holdings centers on the patent litigation update, the reset in expectations around growth and profitability, and how these factors feed into updated valuation frameworks and P/E assumptions.Narrative Update • Jun 04
HRMY: Patent Litigation Resolution And Rare Neurology Pipeline Will Drive Future Upside
Analysts have lifted their price target on Harmony Biosciences Holdings to $75.49 from $62.00, citing recent patent litigation updates, views that prior share price weakness related to intellectual property concerns was excessive, and refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E. Analyst Commentary Bullish analysts are framing the recent patent litigation update as a key clearing event for Harmony Biosciences Holdings, arguing that a major source of uncertainty has now been reduced.
Narrative Update • May 17
HRMY: Future Franchise Balance Will Reflect Patent Risks And Pediatric Expansion
Analysts recently lifted the fair value estimate for Harmony Biosciences Holdings to $28.00 from $25.00, citing updated views on patent litigation risks, intellectual property overhang, and longer term Wakix cash flow scenarios. These updates are reflected in slightly higher discount rates, modestly weaker revenue growth assumptions, a higher profit margin outlook, and a small change in future P/E expectations.Analysis Article • May 14
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) earnings announcement last week didn't impress shareholders...Analysis Article • May 11
Harmony Biosciences Holdings, Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next
As you might know, Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) last week released its latest first-quarter, and...Narrative Update • Apr 21
HRMY: Patent Trial Outcome And Exclusivity Timeline Will Drive Future Upside
Harmony Biosciences' blended analyst price target has moved lower into a $28 to $36 range, as analysts factor in updated Wakix patent trial commentary, the possibility of earlier generic entry, and reduced confidence in retaining cash flows past 2028. Analyst Commentary Recent research updates have generally moved toward more cautious stances on Harmony Biosciences, with several firms cutting price targets and shifting ratings to Hold or Underperform.Narrative Update • Apr 06
HRMY: Earlier Patent Setback Risk Will Drive Bearish Franchise Repricing
Harmony Biosciences Holdings' latest narrative update reflects a steady fair value estimate alongside a reset in Street price targets, with several analysts trimming their views into a $28 to $36 range as they factor in increased Wakix patent uncertainty and the potential timing of generic entries. Analyst Commentary Recent research updates cluster around a more cautious stance on Harmony Biosciences, with several bearish analysts trimming price targets into the US$28 to US$36 band and shifting ratings toward more neutral positions.Narrative Update • Mar 23
HRMY: Patent Trial Outcomes Will Shape Future Upside Potential
Narrative Update on Harmony Biosciences Holdings The analyst price target range for Harmony Biosciences has been revised lower, with recent cuts to $30, $36 and $28 as analysts factor in increased Wakix patent uncertainty, potential earlier generic entry, and more conservative assumptions around long term cash flows and exclusivity. Analyst Commentary Recent Street research has leaned more cautious on Harmony Biosciences, with several firms trimming price targets and, in some cases, lowering ratings following developments in Wakix patent litigation and updated cash flow assumptions.Narrative Update • Mar 09
HRMY: Earlier Generic Threat To Key Franchise Will Drive Share Repricing
Analysts have reduced their average price target on Harmony Biosciences to $25 from $31. They cite higher perceived patent and exclusivity risks around Wakix, along with more conservative assumptions for long term cash flows and future P/E levels.
Narrative Update • Feb 23
HRMY: Legal Overhang On Key Sleep Franchise Will Shape Future Upside
Analysts have modestly lifted their fair value estimate for Harmony Biosciences Holdings from about $46.45 to roughly $47.30, while highlighting legal and generic entry risks to the Wakix franchise and reflecting these concerns in more cautious price targets and ratings. Analyst Commentary Recent Street research around Harmony Biosciences focuses heavily on legal outcomes for Wakix and the timing of potential generic entry, with valuation work and ratings increasingly framed through that risk lens.Narrative Update • Feb 09
HRMY: Sleep Disorder Pipeline And 2025 Outlook Will Support Future Upside
Analysts have trimmed their price target on Harmony Biosciences Holdings to US$45 from US$48, reflecting updated modeling while maintaining that their fundamental outlook for the business from 2025 remains intact. Analyst Commentary Analysts see the revised US$45 price target as a fine tuning of their models rather than a shift in their core stance on Harmony Biosciences Holdings from 2025 onward.Narrative Update • Jan 25
HRMY: Long-Term Sleep Disorder Pipeline Will Drive Future Upside Potential
Narrative Update The analyst price target for Harmony Biosciences Holdings has been revised slightly higher to about $46.45 from roughly $44.55, as analysts refresh their models to reflect updated sales ramps, guidance tweaks, and modestly adjusted long term assumptions for discount rates, margins, and P/E multiples. Analyst Commentary Recent research on Harmony Biosciences Holdings reflects a mix of optimism around execution and caution on valuation and growth durability, which helps explain why the average price target has shifted only modestly.Narrative Update • Jan 11
HRMY: Raised Guidance And Product Pipeline Progress Will Support Bullish Upside Potential
Analysts have slightly reduced their price targets on Harmony Biosciences Holdings, with moves such as Truist trimming its target to $45 from $48 and BofA nudging its target to $32 from $31. They cited updated models that reflect modestly adjusted sales ramps and guidance, while keeping core views on the business intact.Narrative Update • Dec 26
HRMY: Raised Guidance And Strengthening Launch Ramp Will Support Bullish Upside Potential
Analysts have raised their price target on Harmony Biosciences Holdings by $1 to $32, citing a slightly stronger near term launch ramp and 2% upward revisions to Wakix sales forecasts through 2027. Analyst Commentary Bullish analysts point to the improved price target as evidence that execution on the current launch is tracking slightly ahead of prior expectations.Narrative Update • Dec 12
HRMY: Raised Guidance And Core Franchise Strength Will Support Bullish Upside Potential
Analysts have modestly lowered their fair value estimate for Harmony Biosciences Holdings to $62.00 from $70.00, citing tempered long term revenue growth and profit margin expectations, despite slightly higher near term Wakix sales forecasts and recent price target revisions on the Street. Analyst Commentary Bullish analysts acknowledge that the modest trimming of fair value largely reflects more conservative long term assumptions, while near term fundamentals remain resilient.Analysis Article • Nov 20
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 28% Share Price Climb
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders are no doubt pleased to see that the share price has...Narrative Update • Sep 26
Expanding Sleep And Rare Disease Markets Will Unlock Future Potential
Analysts have reduced Harmony Biosciences’ price target from $50.45 to $44.55, citing negative Phase 3 data for ZYN002 in fragile X syndrome and competitive risks to Wakix, though future catalysts remain, resulting in a more cautious near-term outlook. Analyst Commentary Negative Phase 3 data for ZYN002 in fragile X syndrome raises concerns over Harmony's near-term growth prospects, compounded by the absence of detailed management commentary.Analysis Article • Sep 11
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analysis Article • Jun 26
Harmony Biosciences Holdings (NASDAQ:HRMY) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 20
A Piece Of The Puzzle Missing From Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) 26% Share Price Climb
Those holding Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shares would be relieved that the share price has...Analysis Article • May 13
Why Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Are Better Than They Seem
Shareholders appeared to be happy with Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) solid earnings report last...Analysis Article • May 09
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Shareholders of Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) will be pleased this week, given that the stock...Seeking Alpha • Mar 24
Harmony Biosciences: A Compelling Risk-Reward Opportunity
Summary Harmony Biosciences offers a promising investment with one commercial drug, WAKIX, and a robust pipeline, despite some setbacks and risks. The company’s financial health is strong, with significant cash reserves and manageable debt, supporting future R&D and commercialization efforts. Fair value estimates suggest a 70% upside, with a base case valuation of $59.94, and even in a pessimistic scenario, the stock appears fairly valued. Due to dependence on WAKIX, I recommend a cautious 0.5x position, with potential adjustments based on upcoming trial results and stock performance. Read the full article on Seeking AlphaAnalysis Article • Feb 28
Harmony Biosciences Holdings, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) filed its full-year result this...Analysis Article • Feb 15
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Shares Not Telling The Full Story
It's not a stretch to say that Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio...Seeking Alpha • Jan 24
Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech
Summary Harmony Biosciences Holdings, Inc.'s Wakix, a first-in-class drug for narcolepsy, has shown strong revenue growth and recent label expansion to pediatric patients, with good future growth potential. Despite past challenges, including a short attack and a failed Phase 3 study, Harmony's stock has rebounded, supported by solid financials and strategic product extensions. Harmony's diversified pipeline, including new indications for pitolisant / Wakix, and other Phase 3 candidates, positions it for significant revenue growth and reduced single-asset risk. With strong financial metrics, profitability, and a well-planned growth strategy, HRMY stock is undervalued, making it a compelling “Buy” opportunity for 2025 in my view. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
Summary Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth. The global hypersomnia market industry is expected to grow to $5 billion by 2032. Read the full article on Seeking AlphaAnalysis Article • Oct 31
Harmony Biosciences Holdings, Inc. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) came out with its quarterly results last week, and we wanted to see...Analysis Article • Oct 30
Is Harmony Biosciences Holdings (NASDAQ:HRMY) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 25
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
There wouldn't be many who think Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E...
New Narrative • Sep 11
Pitolisant HD's Innovations And Critical Expansions Set To Surge Revenue And Solidify Market Dominance
Expanding the patient base and treatment efficacy for narcolepsy with the high-dose program of pitolisant and pursuing additional indications will significantly grow future revenues.Seeking Alpha • Aug 15
Harmony Biosciences: Advancing An Expanded Pipeline
Summary Today, we are revisiting the biopharma name Harmony Biosciences for the first time in nearly a year and a half. The company is nicely profitable thanks to its flagship product WAKIX and Harmony has a solid balance sheet as well. Harmony Biosciences has made some recent acquisitions that greatly expanded its pipeline and peak sales potential. An updated analysis of Harmony Biosciences stock follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Jul 15
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jun 07
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio of 12.6x might make it look...Analysis Article • May 03
Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a good week for Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) shareholders, because the company has just...Analysis Article • Apr 04
These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Feb 09
Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) price-to-earnings (or "P/E") ratio of 13.1x might make it look...Shareholder Returns
| HRMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.2% | -1.2% | 0.1% |
| 1Y | 4.8% | 50.7% | 18.9% |
Return vs Industry: HRMY underperformed the US Pharmaceuticals industry which returned 49.9% over the past year.
Return vs Market: HRMY underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| HRMY volatility | |
|---|---|
| HRMY Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HRMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HRMY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 293 | Jeffrey Dayno | www.harmonybiosciences.com |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD).
Harmony Biosciences Holdings, Inc. Fundamentals Summary
| HRMY fundamental statistics | |
|---|---|
| Market cap | US$2.22b |
| Earnings (TTM) | US$181.27m |
| Revenue (TTM) | US$959.90m |
12.3x
P/E Ratio2.3x
P/S RatioIs HRMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRMY income statement (TTM) | |
|---|---|
| Revenue | US$959.90m |
| Cost of Revenue | US$235.91m |
| Gross Profit | US$723.99m |
| Other Expenses | US$542.72m |
| Earnings | US$181.27m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.11 |
| Gross Margin | 75.42% |
| Net Profit Margin | 18.88% |
| Debt/Equity Ratio | 15.4% |
How did HRMY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/17 05:52 |
| End of Day Share Price | 2026/08/17 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harmony Biosciences Holdings, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Charles Duncan | Cantor Fitzgerald & Co. |